# Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

> **NCT02656069** · PHASE3 · COMPLETED · sponsor: **Xeris Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Hypoglycemia
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** G-Pen (glucagon injection)
- **DRUG:** Lilly Glucagon (glucagon injection [rDNA origin])

## Key facts

- **NCT ID:** NCT02656069
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2017-08-14
- **Final completion:** 2017-09-25
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02656069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02656069, "Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02656069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*